The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of high-sensitivity C-reactive protein (hs-CRP), a measure of inflammation, through 90 days. Study participants treated with a placebo showed hs-CRP reductions of 15%.

Mexico halts Brazilian poultry imports after a bird flu outbreak, the U.S. FDA conditionally approves Novavax's COVID vaccine, and allows the first Alzheimer's blood test. Meanwhile, Assura is outbid by PHP in a takeover,

BofA Securities 2025 Health Care Conference May 14, 2025 6:00 PM ETCompany ParticipantsJohn Jacobs - President and CEOJim